EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Developing a Phosphodiesterase 10A Inhibitor as a Novel Therapeutic Agent for Triple-Negative Breast Cancer

Mrityunjoy Biswas, Md Manirujjaman iD, Jovanny Zabaleta, Dorota Wyczechowska iD, Jone Garai, Qingzhao Yu iD, Luis Del Valle iD, Samarpan Majumder iD, Timothy Kayes, Xi Chen, Adam B Keeton, Lucio Miele iD und 4 weitere

Cells · 2026

DOI: 10.3390/cells15151374 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cells, 2026. Verfasst von Mrityunjoy Biswas und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Genetics, Louisiana State University Health Sciences Center-New Orleans (LSUHSC-NO), New Orleans, LA 70112, USA. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Phosphodiesterase Inhibitors, Phosphoric Diester Hydrolases, Antineoplastic Agents. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIGMS NIH HHS, NCI NIH HHS, NIH COBRE.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Triple-negative breast cancer (TNBC) is a highly aggressive subtype of breast cancer with limited therapeutic options for patients at high risk of disease recurrence and metastasis. The cyclic nucleotide-degrading enzyme, phosphodiesterase 10A (PDE10), that hydrolyzes both cAMP and cGMP has been previously reported to be expressed in multiple cancers and regulates key cellular signaling pathways involved in cancer cell proliferation, survival, and maintenance of stem cell-like properties. We found that PDE10 overexpression was associated with poor relapse-free survival of TNBC patients and identified its potential as a therapeutic target for TNBC using a novel inhibitor, ADT-030. Our results showed that ADT-030 inhibited the growth of TNBC cells, reduced colony-forming efficiency and enhanced the therapeutic efficacy of paclitaxel. A TNBC mouse model demonstrated that oral administration of ADT-030 significantly suppressed syngeneic tumor growth and enhanced the antitumor efficacy of paclitaxel. ADT-030 treatment altered differentially expressed genes (DEGs), signaling pathways, and cellular processes. Overall, our findings suggest that ADT-030, as a monotherapy or in combination with standard-of-care chemotherapy, may be an effective therapeutic approach for TNBC. Further studies are warranted to better understand the oncogenic role of PDE10 in TNBC and the mechanisms by which ADT-030 modulates the tumor microenvironment (TME) and enhances chemotherapy response.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Triple Negative Breast NeoplasmsPhosphodiesterase InhibitorsPhosphoric Diester HydrolasesAntineoplastic AgentsAnimalsFemaleHumansPaclitaxelCell Line, TumorMiceCell ProliferationGene Expression Regulation, NeoplasticXenograft Model Antitumor AssaysSignal Transduction

Stichwörter der Autor:innen

ADT-030PDE10TNBCmammospherespaclitaxel

Substanzen

Phosphodiesterase InhibitorsPaclitaxelPhosphoric Diester HydrolasesAntineoplastic Agents

Autor:innen und Institutionen

  • Department of Genetics, Louisiana State University Health Sciences Center-New Orleans (LSUHSC-NO), New Orleans, LA 70112, USA.
  • Department of Interdisciplinary Oncology, Louisiana State University Health Sciences Center-New Orleans (LSUHSC-NO), New Orleans, LA 70112, USA.
  • School of Public Health, Louisiana State University Health Sciences Center-New Orleans (LSUHSC-NO), New Orleans, LA 70112, USA.
  • Department of Pathology, Louisiana State University Health Sciences Center-New Orleans (LSUHSC-NO), New Orleans, LA 70112, USA.
  • Department of Drug Discovery & Development, Harrison College of Pharmacy, Auburn University, Auburn, AL 36849, USA.
  • LSU-LCMC Health Cancer Center, New Orleans, LA 70112, USA.

ORCID-Profile: Md Manirujjaman, Dorota Wyczechowska, Qingzhao Yu, Luis Del Valle, Samarpan Majumder, Lucio Miele, Yulia Y Maxuitenko, Gary A Piazza

Förderung

  • NIGMS NIH HHS
  • NCI NIH HHS
  • NIH COBRE
  • NIGMS
  • LSU Health REP
  • NIH

Zitieren

APA

Biswas, M., Manirujjaman, M., Zabaleta, J., Wyczechowska, D., Garai, J., Yu, Q., Del Valle, L., Majumder, S., Kayes, T., Chen, X., Keeton, A. B., Miele, L., Maxuitenko, Y. Y., Li, N., Piazza, G. A., & Hossain, F. (2026). Developing a Phosphodiesterase 10A Inhibitor as a Novel Therapeutic Agent for Triple-Negative Breast Cancer. Cells. https://doi.org/10.3390/cells15151374

Vancouver

Biswas M, Manirujjaman M, Zabaleta J, Wyczechowska D, Garai J, Yu Q, et al. Developing a Phosphodiesterase 10A Inhibitor as a Novel Therapeutic Agent for Triple-Negative Breast Cancer. Cells. 2026. doi:10.3390/cells15151374

BibTeX
@article{Biswas2026,
  author = {Biswas, Mrityunjoy and Manirujjaman, Md and Zabaleta, Jovanny and Wyczechowska, Dorota and Garai, Jone and Yu, Qingzhao and Del Valle, Luis and Majumder, Samarpan and Kayes, Timothy and Chen, Xi and Keeton, Adam B and Miele, Lucio and Maxuitenko, Yulia Y and Li, Nan and Piazza, Gary A and Hossain, Fokhrul},
  title = {Developing a Phosphodiesterase 10A Inhibitor as a Novel Therapeutic Agent for Triple-Negative Breast Cancer},
  journal = {Cells},
  year = {2026},
  doi = {10.3390/cells15151374}
}
Kostenlos starten →